Octreotide acetate

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Octreotide acetate (Sandostatin) is an octapeptide congener of native somatostatin, inhibits the secretion of insulin and glucagon. It reduces production of IGF-1 and IGF-2 by the liver by modulation of growth-hormone secretion from the pituitary gland. [1] The insulin-like growth factors IGF-1 and IGF-2, endogenously produced polypeptide hormones and potent stimulators of cell proliferation, are under investigation as clinical targets in prostate cancer. Octreotide acetate decreased the urinary excretion of uric acid as well as the plasma concentrations of glucagon and insulin. Octreotide acetate decreased the urinary excretion of sodium and chloride without significiant influence on creatinine clearance, while the concentrations of lactic acid, pyruvic acid in blood, and cyclic AMP in plasma were not changed. [1]
    
    [1] Tetsuya yamamoto, Yuji moriwaki et al. Effect of Octreotide acetate on the Plasma Concentration and Urinary Excretion of Uridine and Purine Bases. Endocrine Journal 2002, 49(2),139-144.
- Properties
  - Categories
    
    octapeptide congener of native somatostatin
    
    Alternative Name
    
    SMS 201995; Sandostatin; (4S,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
    
    CAS Number
    
    79517-01-4
    
    Molecular Formula
    
    C51H70N10O12S2
    
    Molecular Weight
    
    1079.29
    
    Appearance
    
    A solid
    
    Purity
    
    99.74%
    
    Solubility
    
    ≥53.96 mg/mL in DMSO; ≥10.04 mg/mL in EtOH; ≥28.85 mg/mL in H2O
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    O=C(N[[email protected]](CC1=CNC2=CC=CC=C12)C3=O)[[email protected]@H](NC([[email protected]@H](NC([[email protected]](N)CC4=CC=CC=C4)=O)CSSC[[email protected]](C(N[[email protected]@H]([[email protected]](O)C)CO)=O)NC([[email protected]](NC([[email protected]](CCCCN)N3)=O)([H])[[email protected]](O)C)=O)=O)CC5=CC=CC=C5.CC(O)=O
    
    * For Research Use Only
- Reference
  - 1. Gadgil P, Alleyne C, et al. "Assessing the Utility of In Vitro Screening Tools for Predicting Bio-Performance of Oral Peptide Delivery." Pharm Res. 2019 Aug 26;36(10):151. PMID:31451949